

AMGEN INC  
Form 4  
August 08, 2012

# FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
REASON J PAUL

(Last) (First) (Middle)

ONE AMGEN CENTER DRIVE

(Street)

THOUSAND  
OAKS, CA 91320-1799

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
AMGEN INC [AMGN]

3. Date of Earliest Transaction (Month/Day/Year)  
08/06/2012

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|
|                                 |                                      |  | Code                           | V   | Amount  | (A) or (D)   | Price                             |
| Common Stock                    | 08/06/2012                           |  | M                              |   | 5,000   | A  | \$ 62.55                          |
| Common Stock                    | 08/06/2012                           |  | M                              |   | 5,000   | A  | \$ 42.13                          |
| Common Stock                    | 08/06/2012                           |  | M                              |   | 5,000   | A  | \$ 50.44                          |
| Common Stock                    | 08/06/2012                           |  | M                              |   | 5,000   | A  | \$ 58.43                          |
| Common Stock                    | 08/06/2012                           |  | M                              |   | 5,000   | A  | \$ 54.69                          |
|                                 |                                      |  |                                |   |   |  | 24,408                            |
|                                 |                                      |  |                                |   |   |  | 29,408                            |
|                                 |                                      |  |                                |   |   |  | 34,408                            |
|                                 |                                      |  |                                |   |   |  | 39,408                            |
|                                 |                                      |  |                                |   |   |  | 44,408                            |
|                                 |                                      |  |                                |   |   |  | D                                 |
|                                 |                                      |  |                                |   |   |  | D                                 |
|                                 |                                      |  |                                |   |   |  | D                                 |
|                                 |                                      |  |                                |   |   |  | D                                 |
|                                 |                                      |  |                                |   |   |  | D                                 |

Edgar Filing: AMGEN INC - Form 4

|              |            |   |       |   |          |                       |   |
|--------------|------------|---|-------|---|----------|-----------------------|---|
| Common Stock | 08/06/2012 | F | 3,805 | D | \$ 82.21 | 40,603                | D |
| Common Stock | 08/06/2012 | F | 2,563 | D | \$ 82.21 | 38,040                | D |
| Common Stock | 08/06/2012 | F | 3,068 | D | \$ 82.21 | 34,972                | D |
| Common Stock | 08/06/2012 | F | 3,554 | D | \$ 82.21 | 31,418                | D |
| Common Stock | 08/06/2012 | F | 3,327 | D | \$ 82.21 | 28,091 <sup>(1)</sup> | D |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Amount or Number of Shares |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|-------------------------------|
| Nqso (Right to Buy)                        | \$ 62.55   | 08/06/2012                           |  | M                              | 5,000   | 04/26/2007 04/26/2014                                    | Common Stock  | 5,000                         |
| Nqso (Right to Buy)                        | \$ 42.13   | 08/06/2012                           |  | M                              | 5,000   | 04/29/2008 04/29/2015                                    | Common Stock  | 5,000                         |
| Nqso (Right to Buy)                        | \$ 50.44   | 08/06/2012                           |  | M                              | 5,000   | 04/28/2009 04/28/2016                                    | Common Stock  | 5,000                         |
| Nqso (Right to Buy)                        | \$ 58.43   | 08/06/2012                           |  | M                              | 5,000   | 04/26/2010 04/26/2020                                    | Common Stock  | 5,000                         |
| Nqso (Right to Buy)                        | \$ 54.69   | 08/06/2012                           |  | M                              | 5,000   | 04/25/2011 04/25/2021                                    | Common Stock  | 5,000                         |

Buy)

## Reporting Owners

| Reporting Owner Name / Address  | Relationships |           |         |       |
|---|---------------|-----------|---------|-------|
|   | Director      | 10% Owner | Officer | Other |
| REASON J PAUL<br>ONE AMGEN CENTER DRIVE<br>THOUSAND OAKS, CA 91320-1799 | X             |           |         |       |

## Signatures

/s/ Andrea Robinson, Attorney-in-Fact for Adm.  
Reason 08/08/2012

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) These shares include 124 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's unvested, and vested but deferred, Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.